Oncogenes y Dianas Efectoras
PANCCUN
Fundación Jiménez Díaz
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (3)
2024
-
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
Clinical Cancer Research, Vol. 30, Núm. 14, pp. 2945-2953
2023
-
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229
2022
-
Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
European Journal of Cancer, Vol. 174, pp. S116